Emerging studies suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and GIP , appears to offer a notable development for weight management . Preliminary clinical trials have shown considerable losses in abdominal mass , possibly exceeding other weight-loss therapies . However , further assessment is required to thoroughly det